Creative Medical Technology Holdings, Inc. (CELZ)
| Previous close | 4.3500 |
| Open | 4.5400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.3937 - 4.3937 |
| 52-week range | 3.9300 - 10.2812 |
| Volume | |
| Avg. volume | 218,145 |
| Market cap | 5.961M |
| Beta (5Y monthly) | 5.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.7600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireCreative Medical Technology Holdings Provides Corporate Update
PHOENIX, March 27, 2024--Creative Medical Technology Holdings, Inc., ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
Simply Wall St.Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Creative Medical Technology Holdings ( NASDAQ:CELZ ) Full Year 2023 Results Key Financial Results Net loss: US$5.29m...
Business WireCreative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
PHOENIX, March 07, 2024--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
